SVB Securities analyst Joseph Schwartz downgraded Applied Molecular Transport to Market Perform from Outperform with a price target of $2, down from $15, after the company announced the Phase 2 LOMBARD trial of its lead candidate AMT-101 in monotherapy for treating ulcerative colitis did not meet the primary endpoint.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMTI:
- Street Wrap: Today’s Top Upgrades, Downgrades, Initiations
- Applied Molecular Transport downgraded to Market Perform from Outperform at JMP Securities
- Applied Molecular Transport downgraded to Market Perform at JMP Securities
- Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
- Applied Molecular Transport announces phase 2 results from Oral AMT-101 trial
